Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile —commonly known as C. diff —are a serious and persistent problem for patients and ...

Researchers at Tufts University School of Medicine are studying C. diff at multiple levels, from how individual bacterial ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary ...

About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual ...

BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...